Gearing up for a phase 3 clinical trial of its coronavirus vaccine candidate, mRNA-1273, Moderna (NASDAQ:MRNA) is apparently butting heads with federal government officials.

Tensions between the company and the officials have delayed the start of the trial.

Both Moderna and government entities involved in the mRNA-1273 project have denied strains in the relationship.

The company is part of the federal Operation Warp Speed program aimed at rapidly developing an effective coronavirus vaccine, and its mRNA-1273 is the first candidate to be entering a phase 3 trial